Can "early" and "late" 18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?

Radiotherapy and Oncology

Volumn 103, Issue 1, 2012, Pages 63-68

  Castaldi, Paola ^a   Rufini, Vittoria ^a   Bussu, Francesco ^b   Miccichè, Francesco ^b   Dinapoli, Nicola ^b   Autorino, Rosa ^b   Lago, Mariaelena ^a   De Corso, Eugenio ^b   Almadori, Giovanni ^b   Galli, Jacopo ^b   Paludetti, Gaetano ^b   Giordano, Alessandro ^a   Valentini, Vincenzo ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

18F FDG PET CT; Head and neck carcinomas; Radio chemotherapy; Response evaluation

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE; MALE; METABOLISM; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; HEAD AND NECK TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME;

EID: 84859727876     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.03.001     Document Type: Article

References (41)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709. (Pubitemid 351671886)
2. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-6. (Pubitemid 30019568)
3. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76. (Pubitemid 41095116)
4. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508. (Pubitemid 351355215)
5. Bussink J, van Herpen CM, Kaanders JH, Oyen WJ. PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol 2010;11:661-9.
6. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46:983-95. (Pubitemid 43733514)
7. Menda Y, Graham MM. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers. Semin Nucl Med 2005;35:214-9. (Pubitemid 41253360)
8. Malone JP, Gerberi MA, Vasireddy S, et al. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography. Arch Otolaryngol Head Neck Surg 2009;135:1119-25.
9. Schöder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009;50:74S-88S.
10. Kao J, Vu HL, Genden EM, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer 2009;115:4586-94.
11. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:24-9.
12. Passero VA, Branstetter BF, Shuai Y, et al. Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol 2010;21:2278-83.
13. Edet-Sanson A, Dubray B, Doyeux K, et al. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC). Radiother Oncol 2012;102:251-7.
14. Castadot P, Geets X, Lee JA, Grégoire V. Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? Radiother Oncol 2011;101:343-50.
15. Rosenberg R, Herrmann K, Gertler R, et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis 2009;24:191-200.
16. Janssen MH, Ollers MC, Riedl RG, et al. Accurate prediction of pathological rectal tumour response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys 2010;77:392-9.
17. Wu X, Dastidar P, Pertovaara H, et al. Early treatment response evaluation in patients with diffuse large B-cell lymphoma - a pilot study comparing volumetric MRI and PET/CT. Mol Imaging Biol 2011;13:785-92.
18. Furth C, Steffen IG, Amthauer H, et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 2009;27:4385-91.
19. Van Loon J, Offermann C, Ollers M, van Elmpt W, Vegt E, Rahmy A. Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. Radiother Oncol 2011;99:172-5.
20. Meignan M, Itti E, Gallamini A, Haioun C. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation - where do we stand? Leuk Lymphoma 2009;50:1753-6.
21. Brun E, Kjellén E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127-35. (Pubitemid 34111509)
22. Farrag A, Ceulemans G, Voordeckers M, Everaert H, Storme G. Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun 2010;31:495-501.
23. Ceulemans G, Voordeckers M, Farrag A, Verdries D, Storme G, Everaert H. Can 18F-FDG-PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumour response in head-and-neck cancer? Int J Radiat Oncol Biol Phys 2011;81:938-42.
24. Hentschel M, Appold S, Schreiber A, et al. Serial FDG-PET on patients with head and neck cancer: implications for radiation therapy. Int J Radiat Biol 2009;85:796-804.
25. Greene FL, Sobin LH. The TNM system: our language for cancer care. J Surg Oncol 2002;80:119-20. (Pubitemid 34747614)
26. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82. (Pubitemid 29512308)
27. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010;195:310-20.
28. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45:56-68. (Pubitemid 47611611)
29. Hah JP, Patel KJ. Head and Neck Surgery and Oncology. 3rd ed. Edinburgh: Mosby Ltd.; 2003.
30. Bosch FX, Ritter D, Enders C, et al. Head and neck tumour sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer 2004;111:530-8. (Pubitemid 39045319)
31. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
32. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 2010;51:866-74.
33. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemotherapy. Clin Otolaryngol 2008;33:210-22. (Pubitemid 351799005)
34. Greven KM, Williams 3rd DE, McGuirt Sr WF, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001;23:942-6. (Pubitemid 32977536)
35. Murphy JD, La TH, Chu K, et al. Postradiation metabolic tumour volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;80:514-21.
36. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D- glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-9. (Pubitemid 23141556)
37. Wouter BG, Koritzinsky M. The tumour microenvironment and cellular hypoxia responses. In: Basic clinical radiobiology. 4th ed., London: Edward Arnold. 2009, pp. 217-32.
38. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757. (Pubitemid 44832019)
39. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011;101:369-75.
40. Postema EJ, McEwan AJ, Riauka TA, et al. Initial results of hypoxia imaging using 1-alpha-D-(5-deoxy-5-[18F]-fluroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med mol Imaging 2009;36:1565-73.
41. Hentschel M, Appold S, Scrreiber A, et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 2011;38:1203-11.